title: Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura.
abstract: OBJECTIVE
  The purpose of this study was to compare the efficacy and side effects of intravenous immunoglobulin (IVIG) with intravenous anti-D immunoglobulin for treatment of newly diagnosed acute childhood Idiopathic thrombocytopenic purpura (ITP).
  
  
  METHODS
  Children (6 months to 14 years) with newly diagnosed acute ITP and platelet count below 20,000/ microL were randomized to receive single dose intravenous 75 microg/kg anti-D or 1g/kg IVIG for two consecutive days (total dose 2 g/kg). Response rate defined as a platelet count over 20,000 / microL 72 hours after initial treatment.
  
  
  RESULTS
  Eighty one patients (52 male and 29 female) with mean age of 5 years and 3 months randomly divided in anti-D group (n=42) and IVIG group (n=39). Mean baseline (pretreatment) platelet counts were 15406 / microL and 15230/ microL in anti-D and IVIG group, respectively. The response rate in IVIG group (98%) was more significant than anti-D group (76%); (P = 0.017). After 7 days the platelet counts of all patients in IVIG group were more than 20,000/ microL while in anti-D group 12% had platelet counts below 20,000/ microL.
  
  
  CONCLUSIONS
  In acute childhood ITP, initial treatment with IVIG (2g/Kg in divided dose) increased platelet count more rapidly and more significant than intravenous anti-D (single dose of 75 microg/kg) within the first 72 hours.
authors.affiliation: Division of Hematology/Oncology, Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran. eshahgholi@sina.tums.ac.ir
authors.forename: Elham
authors.initials: E
authors.lastname: Shahgholi
authors.forename: Parvaneh
authors.initials: P
authors.lastname: Vosough
authors.forename: Kambiz
authors.initials: K
authors.lastname: Sotoudeh
authors.forename: Khadijeh
authors.initials: K
authors.lastname: Arjomandi
authors.forename: Shahla
authors.initials: S
authors.lastname: Ansari
authors.forename: Soraya
authors.initials: S
authors.lastname: Salehi
authors.forename: Mohammad
authors.initials: M
authors.lastname: Faranoush
authors.forename: Mohammad Ali
authors.initials: MA
authors.lastname: Ehsani
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood / Q000188:drug therapy*; D018029:Rho(D) Immune Globulin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D018029:Rho(D) Immune Globulin